AMRN Overview

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Amarin Corporation PLC revenue for the last quarter amounts to 43.33M USD, increased 3.12

Amarin Corporation PLC. EPS for the last quarter amounts to -0.50 USD, decreased -34.21

Amarin Corporation PLC (AMRN) has 80 emplpoyees as of May 08 2026.

Today AMRN has the market capitalization of 311.18M USD.